Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LIGAND PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for LIGAND PHARMACEUTICALS INC

LGND LGNDZ LGNXZ LGNYZ LGNZZ

LIGAND PHARMACEUTICALS INC

About LIGAND PHARMACEUTICALS INC

Ligand Pharmaceuticals is a biopharmaceutical company specializing in supporting drug development through licensing, licensing technology, and royalty rights. It focuses on late-stage assets, infrastructure-light platform technologies like Captisol and NITRICIL, and partnerships with leading pharma firms. Revenue streams include royalties, product sales, and milestone payments, with a diversified portfolio aimed at high-margin, low-infrastructure operations in global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LIGAND PHARMACEUTICALS INC

1
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 14% Revenue Growth to $51.7 Million in Q1 2026

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 60% Revenue Growth to $268.1 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 123% Revenue Growth and $117.3 Million Net Income in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 15% Revenue Growth to $47.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports $42.5 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 27% Revenue Growth to $167.1 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
LIGAND PHARMACEUTICALS INC Ligand Pharmaceuticals Reports 58% Revenue Growth in Q3 2024, Completes Strategic Acquisitions

Via official filing (AI summary) | over 1 year ago | 0 comments